Jean-Paul St-Pierre
Keine laufenden Positionen mehr
Profil
Jean-Paul St-Pierre formerly worked at Synapse Technologies, Inc., as President & Chief Executive Officer, Ambrilia Biopharma, Inc., as Director from 2007 to 2010, Sandoz Canada, Inc., as Vice President-Scientific Development, Rhône-Poulenc, Inc., as VP-Worldwide Clinical Development Operations, and Hoechst Marion Roussel Canada, Inc., as Executive Vice President-Scientific Affairs.
Dr. St-Pierre received his doctorate degree from the University of Montréal.
Ehemalige bekannte Positionen von Jean-Paul St-Pierre
| Unternehmen | Position | Ende |
|---|---|---|
Ambrilia Biopharma, Inc.
 Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Direktor/Vorstandsmitglied | 31.03.2010 |
| Hoechst Marion Roussel Canada, Inc. | Technik-/Wissenschafts-/F&E-Leiter | - |
| Rhône-Poulenc, Inc. | Technik-/Wissenschafts-/F&E-Leiter | - |
Synapse Technologies, Inc.
 Synapse Technologies, Inc. Pharmaceuticals: MajorHealth Technology Synapse Technologies Inc. develops an Alzheimer's diagnostic test and potential blood/brain drug delivery mechanism based on the p97 protein. | Präsident | - |
Sandoz Canada, Inc.
 Sandoz Canada, Inc. Pharmaceuticals: MajorHealth Technology Sandoz Canada, Inc. develops, manufactures, and distributes injections and ophthalmic pharmaceutical products for the hospital and retail markets. It offers ampoules, vials ophthalmic solutions, suspensions and ointments, and suppositories. The company was founded in 1973 and is headquartered in Boucherville, Canada. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Jean-Paul St-Pierre
| University of Montréal | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Health Technology |
Sandoz Canada, Inc.
Sandoz Canada, Inc. Pharmaceuticals: MajorHealth Technology Sandoz Canada, Inc. develops, manufactures, and distributes injections and ophthalmic pharmaceutical products for the hospital and retail markets. It offers ampoules, vials ophthalmic solutions, suspensions and ointments, and suppositories. The company was founded in 1973 and is headquartered in Boucherville, Canada. | Health Technology |
Synapse Technologies, Inc.
Synapse Technologies, Inc. Pharmaceuticals: MajorHealth Technology Synapse Technologies Inc. develops an Alzheimer's diagnostic test and potential blood/brain drug delivery mechanism based on the p97 protein. | Health Technology |
| Rhône-Poulenc, Inc. | Process Industries |
| Hoechst Marion Roussel Canada, Inc. |
